From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance-a review.
Antimicrobial resistance
CRISPR medicine
CRISPR technology
CRISPR-Cas
Gene editing
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
30
08
2024
accepted:
01
10
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
The growing challenge of antimicrobial resistance (AMR) poses a significant and increasing risk to public health worldwide, necessitating innovative strategies to restore the efficacy of antibiotics. The precise genome-editing abilities of the CRISPR-Cas system have made it a potent instrument for directly targeting and eliminating antibiotic resistance genes. This review explored the mechanisms and applications of CRISPR-Cas systems in combating AMR. The latest developments in CRISPR technology have broadened its potential use, encompassing programmable antibacterial agents and improved diagnostic methods for antibiotic-resistant infections. Nevertheless, several challenges must be overcome for clinical success, including the survival of resistant bacteria, generation of anti-CRISPR proteins that reduce effectiveness, and genetic modifications that change target sequences. Additionally, the efficacy of CRISPR-Cas systems differs across bacterial species, making their universal application challenging. After overcoming these challenges, CRISPR-Cas has the potential to revolutionize AMR treatment, restore antibiotic efficacy, and reshape infection control.
Identifiants
pubmed: 39404843
doi: 10.1007/s00210-024-03509-6
pii: 10.1007/s00210-024-03509-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Abadi S et al (2017) A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action. PLoS Comput Biol 13(10):e1005807
pubmed: 29036168
pmcid: 5658169
doi: 10.1371/journal.pcbi.1005807
Adelman Z et al (2017) Rules of the road for insect gene drive research and testing. Nat Biotechnol 35(8):716–718
pubmed: 28787415
pmcid: 5831321
doi: 10.1038/nbt.3926
Adnyana IMDM et al (2024) CRISPR-Cas9 genome editing technology for zoonotic disease control in Indonesia: a comprehensive review. J Med Health Technol 1(1):21–39
doi: 10.12962/j30466865.v1i1.1172
Allemailem KS (2024) Recent advances in understanding the molecular mechanisms of multidrug resistance and novel approaches of CRISPR/Cas9-based genome-editing to combat this health emergency. Int J Nanomedicine 19:1125–1143
pubmed: 38344439
pmcid: 10859101
doi: 10.2147/IJN.S453566
Allemailem KS et al (2022) Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management. Cancer Commun 42(12):1257–1287
doi: 10.1002/cac2.12366
Allemailem KS et al (2023) Innovative strategies of reprogramming immune system cells by targeting CRISPR/Cas9-based genome-editing tools: a new era of cancer management. Int J Nanomed 18:5531–5559
doi: 10.2147/IJN.S424872
Arthi B, Anand AV, Senthilkumar N, Kalaiselvi S, Krishnapriya S (n.d.) Gene editing using CRISPR/Cas9 system: methods and applications. In: CRISPR and Plant Functional Genomics. CRC Press, pp 258–270
Asadbeigi A et al (2022) CaSilico: a versatile CRISPR package for in silico CRISPR RNA designing for Cas12, Cas13, and Cas14. Front Bioeng Biotechnol 10:957131
pubmed: 36017348
pmcid: 9395711
doi: 10.3389/fbioe.2022.957131
Asmamaw M, Zawdie B (2021) Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics 15:353–361
pubmed: 34456559
pmcid: 8388126
Barman NC et al (2020) CRISPR-Cas9: a promising genome editing therapeutic tool for Alzheimer’s disease—a narrative review. Neurol Ther 9:419–434
pubmed: 33089409
pmcid: 7606404
doi: 10.1007/s40120-020-00218-z
Basgall EM et al (2018) Gene drive inhibition by the anti-CRISPR proteins AcrIIA2 and AcrIIA4 in Saccharomyces cerevisiae. Microbiology 164(4):464–474
pubmed: 29488867
pmcid: 5982135
doi: 10.1099/mic.0.000635
Bikard D, Barrangou R (2017) Using CRISPR-Cas systems as antimicrobials. Curr Opin Microbiol 37:155–160
pubmed: 28888103
doi: 10.1016/j.mib.2017.08.005
Bikard D et al (2014) Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32(11):1146–1150
pubmed: 25282355
pmcid: 4317352
doi: 10.1038/nbt.3043
Biswas A et al (2013) CRISPRTarget: bioinformatic prediction and analysis of crRNA targets. RNA Biol 10(5):817–827
pubmed: 23492433
pmcid: 3737339
doi: 10.4161/rna.24046
Chang Q et al (2015) Antibiotics in agriculture and the risk to human health: how worried should we be? Evol Appl 8(3):240–247
pubmed: 25861382
doi: 10.1111/eva.12185
Charpentier E (2015) CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine. EMBO Mol Med 7(4):363–365
pubmed: 25796552
pmcid: 4403038
doi: 10.15252/emmm.201504847
Chen S et al (2023) A type IF CRISPRi system unveils the novel role of CzcR in modulating multidrug resistance of Pseudomonas aeruginosa. Microbiology Spectrum 11(5):e01123-e1223
pubmed: 37646520
pmcid: 10581170
doi: 10.1128/spectrum.01123-23
Chowdhury S et al (2017) Structure reveals mechanisms of viral suppressors that intercept a CRISPR RNA-guided surveillance complex. Cell 169(1):47-57. e11
pubmed: 28340349
pmcid: 5478280
doi: 10.1016/j.cell.2017.03.012
Citorik RJ, Mimee M, Lu TK (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32(11):1141–1145
pubmed: 25240928
pmcid: 4237163
doi: 10.1038/nbt.3011
Cui L, Bikard D (2016) Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res 44(9):4243–4251
pubmed: 27060147
pmcid: 4872102
doi: 10.1093/nar/gkw223
Davidson AR et al (2020) Anti-CRISPRs: protein inhibitors of CRISPR-Cas systems. Annu Rev Biochem 89:309–332
pubmed: 32186918
pmcid: 9718424
doi: 10.1146/annurev-biochem-011420-111224
De Oliveira DM et al (2020) Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 33(3). https://doi.org/10.1128/cmr.00181-19
Dong H et al (2019) Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli. Int J Antimicrob Agents 53(1):1–8
pubmed: 30267758
doi: 10.1016/j.ijantimicag.2018.09.017
Duan C et al (2021) Harnessing the CRISPR-Cas systems to combat antimicrobial resistance. Front Microbiol 12:716064
pubmed: 34489905
pmcid: 8418092
doi: 10.3389/fmicb.2021.716064
Edgar R, Qimron U (2010) The Escherichia coli CRISPR system protects from λ lysogenization, lysogens, and prophage induction. J Bacteriol 192(23):6291–6294
pubmed: 20889749
pmcid: 2981215
doi: 10.1128/JB.00644-10
Ellakwa DES, Mushtaq N, Khan S, Jabbar A, Abdelmalek MA, Wadan AHS, ... Raza A (2024) Molecular functions of microRNAs in colorectal cancer: recent roles in proliferation, angiogenesis, apoptosis, and chemoresistance. Naunyn-Schmiedeberg's Archives of Pharmacology 1–14
Fage C, Lemire N, Moineau S (2021) Delivery of CRISPR-Cas systems using phage-based vectors. Curr Opin Biotechnol 68:174–180
pubmed: 33360715
doi: 10.1016/j.copbio.2020.11.012
Fantappiè L et al (2014) Antibody-mediated immunity induced by engineered Escherichia coli OMVs carrying heterologous antigens in their lumen. J Extracell Vesicles 3(1):24015
doi: 10.3402/jev.v3.24015
Gasiunas G et al (2012) Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci 109(39):E2579–E2586
pubmed: 22949671
pmcid: 3465414
doi: 10.1073/pnas.1208507109
Gencay YE et al (2024) Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nat Biotechnol 42(2):265–274
pubmed: 37142704
doi: 10.1038/s41587-023-01759-y
Gholizadeh P et al (2020) How CRISPR-Cas system could be used to combat antimicrobial resistance. Infect Drug Resist 13:1111–1121
pubmed: 32368102
pmcid: 7182461
doi: 10.2147/IDR.S247271
Gomaa AA et al (2014) Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio. 5(1). https://doi.org/10.1128/mbio.00928-13
Gómez-Piña JJ et al (2024) Emerging antibiotic resistance: a modern-day horseman of the apocalypse. Int J Res Med Sci 12(3):663
doi: 10.18203/2320-6012.ijrms20240504
Gross P (2024) RNA editing with CRISPR. Nat Genet 56(6):1038–1038
pubmed: 38871864
doi: 10.1038/s41588-024-01816-5
Hajizadeh Y, Badmasti F, Oloomi M (2024) Inhibition of the blaOXA-48 gene expression in Klebsiella pneumoniae by a plasmid carrying CRISPRi-Cas9 system. Gene 910:148332
pubmed: 38431235
doi: 10.1016/j.gene.2024.148332
Hao M et al (2020) CRISPR-Cas9-mediated carbapenemase gene and plasmid curing in carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 64(9). https://doi.org/10.1128/aac.00843-20
Harrington LB et al (2017) A broad-spectrum inhibitor of CRISPR-Cas9. Cell 170(6):1224-1233. e15
pubmed: 28844692
pmcid: 5875921
doi: 10.1016/j.cell.2017.07.037
Harrington LB et al (2020) A scoutRNA is required for some type V CRISPR-Cas systems. Mol Cell 79(3):416-424. e5
pubmed: 32645367
pmcid: 8196889
doi: 10.1016/j.molcel.2020.06.022
Hille F et al (2018) The biology of CRISPR-Cas: backward and forward. Cell 172(6):1239–1259
pubmed: 29522745
doi: 10.1016/j.cell.2017.11.032
Hofer U (2019) The cost of antimicrobial resistance. Nat Rev Microbiol 17(1):3–3
pubmed: 30467331
doi: 10.1038/s41579-018-0125-x
Hossain AA et al (2021) Viral recombination systems limit CRISPR-Cas targeting through the generation of escape mutations. Cell Host Microbe 29(10):1482-1495. e12
pubmed: 34582782
pmcid: 8516739
doi: 10.1016/j.chom.2021.09.001
Høyland-Kroghsbo NM et al (2017) Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system. Proc Natl Acad Sci 114(1):131–135
pubmed: 27849583
doi: 10.1073/pnas.1617415113
Huan YW et al (2023) P1 bacteriophage-enabled delivery of CRISPR-Cas9 antimicrobial activity against Shigella flexneri. ACS Synth Biol 12(3):709–721
pubmed: 36802585
pmcid: 10028697
doi: 10.1021/acssynbio.2c00465
Hutchings MI, Truman AW, Wilkinson B (2019) Antibiotics: past, present and future. Curr Opin Microbiol 51:72–80
pubmed: 31733401
doi: 10.1016/j.mib.2019.10.008
Jahangiri-Manesh A et al (2022) Gold nanorods for drug and gene delivery: an overview of recent advancements. Pharmaceutics 14(3):664
pubmed: 35336038
pmcid: 8951391
doi: 10.3390/pharmaceutics14030664
Jiang F, Doudna JA (2017) CRISPR–Cas9 structures and mechanisms. Annu Rev Biophys 46(1):505–529
pubmed: 28375731
doi: 10.1146/annurev-biophys-062215-010822
Jiang Y et al (2017) CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum. Nat Commun 8(1):15179
pubmed: 28469274
pmcid: 5418603
doi: 10.1038/ncomms15179
Jin M et al (2022) An engineered λ phage enables enhanced and strain-specific killing of enterohemorrhagic Escherichia coli. Microbiol Spectr 10(4):e01271-e1322
pubmed: 35876591
pmcid: 9431524
doi: 10.1128/spectrum.01271-22
Jinek M et al (2012) A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816–821
pubmed: 22745249
pmcid: 6286148
doi: 10.1126/science.1225829
Jorth P et al (2014) Metatranscriptomics of the human oral microbiome during health and disease. MBio 5(2). https://doi.org/10.1128/mbio.01012-14
Kang YK et al (2017) Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance. Bioconjug Chem 28(4):957–967
pubmed: 28215090
doi: 10.1021/acs.bioconjchem.6b00676
Kaplan MF, Kaplan E, Raza A, Demirler M, Baran A, Cengiz S, Adiguzel MC (2024) Evaluation of raw milk samples and vendor-derived Staphylococcus aureus and Coxiella burnetii prevalence in dairy delicatessens in eastern Turkey. Food Science & Nutrition
Khadempar S et al (2019) CRISPR–Cas9 in genome editing: its function and medical applications. J Cell Physiol 234(5):5751–5761
pubmed: 30362544
doi: 10.1002/jcp.27476
Khameneh B et al (2016) Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb Pathog 95:32–42
pubmed: 26911646
doi: 10.1016/j.micpath.2016.02.009
Khoshandam M et al (2024) Clinical applications of the CRISPR/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis 11(1):268–282
pubmed: 37588217
doi: 10.1016/j.gendis.2023.02.027
Kiga K et al (2020) Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun 11(1):2934
pubmed: 32523110
pmcid: 7287087
doi: 10.1038/s41467-020-16731-6
Kim HS, Kweon J, Kim Y (2024) Recent advances in CRISPR-based functional genomics for the study of disease-associated genetic variants. Exp Mol Med 56(4):861–869
pubmed: 38556550
pmcid: 11058232
doi: 10.1038/s12276-024-01212-3
Kundar R, Gokarn K (2022) CRISPR-Cas system: a tool to eliminate drug-resistant gram-negative bacteria. Pharmaceuticals 15(12):1498
pubmed: 36558949
pmcid: 9781512
doi: 10.3390/ph15121498
Le Quesne WJ, Baker-Austin C, Verner-Jeffreys DW, Al-Sarawi HA, Balkhy HH, Lyons BP (2018) Antimicrobial resistance in the Gulf Cooperation Council region: A proposed framework to assess threats, impacts and mitigation measures associated with AMR in the marine and aquatic environment. Environ Int 121:1003–10
pubmed: 29980310
doi: 10.1016/j.envint.2018.06.030
Lee K et al (2017) Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng 1(11):889–901
pubmed: 29805845
pmcid: 5968829
doi: 10.1038/s41551-017-0137-2
Leenay RT, Beisel CL (2017) Deciphering, communicating, and engineering the CRISPR PAM. J Mol Biol 429(2):177–191
pubmed: 27916599
doi: 10.1016/j.jmb.2016.11.024
Leenay RT et al (2016) Identifying and visualizing functional PAM diversity across CRISPR-Cas systems. Mol Cell 62(1):137–147
pubmed: 27041224
pmcid: 4826307
doi: 10.1016/j.molcel.2016.02.031
Lei Y et al (2014) CRISPR-P: a web tool for synthetic single-guide RNA design of CRISPR-system in plants. Mol Plant 7(9):1494–1496
pubmed: 24719468
doi: 10.1093/mp/ssu044
Leon LM, Mendoza SD, Bondy-Denomy J (2018) How bacteria control the CRISPR-Cas arsenal. Curr Opin Microbiol 42:87–95
pubmed: 29169146
doi: 10.1016/j.mib.2017.11.005
Li Y et al (2016) Harnessing type I and type III CRISPR-Cas systems for genome editing. Nucleic Acids Res 44(4):e34–e34
pubmed: 26467477
doi: 10.1093/nar/gkv1044
Li K et al (2020) Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection. MBio 11(2). https://doi.org/10.1128/mbio.00554-20
Lino CA et al (2018) Delivering CRISPR: a review of the challenges and approaches. Drug Delivery 25(1):1234–1257
pubmed: 29801422
pmcid: 6058482
doi: 10.1080/10717544.2018.1474964
Liu C et al (2017) Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release 266:17–26
pubmed: 28911805
pmcid: 5723556
doi: 10.1016/j.jconrel.2017.09.012
Liu H et al (2020) Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria. Theranostics 10(14):6310
pubmed: 32483454
pmcid: 7255016
doi: 10.7150/thno.42573
Lu M et al (2017) Recent advances on extracellular vesicles in therapeutic delivery: challenges, solutions, and opportunities. Eur J Pharm Biopharm 119:381–395
pubmed: 28739288
doi: 10.1016/j.ejpb.2017.07.010
Ma J et al (2016) CRISPR-DO for genome-wide CRISPR design and optimization. Bioinformatics 32(21):3336–3338
pubmed: 27402906
pmcid: 6095119
doi: 10.1093/bioinformatics/btw476
Makarova KS et al (2020) Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol 18(2):67–83
pubmed: 31857715
doi: 10.1038/s41579-019-0299-x
Marbouty M et al (2017) Scaffolding bacterial genomes and probing host-virus interactions in gut microbiome by proximity ligation (chromosome capture) assay. Sci Adv 3(2):e1602105
pubmed: 28232956
pmcid: 5315449
doi: 10.1126/sciadv.1602105
Marino ND et al (2018) Discovery of widespread type I and type V CRISPR-Cas inhibitors. Science 362(6411):240–242
pubmed: 30190308
pmcid: 6520112
doi: 10.1126/science.aau5174
Marino ND et al (2020) Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies. Nat Methods 17(5):471–479
pubmed: 32203383
pmcid: 8510557
doi: 10.1038/s41592-020-0771-6
Montague TG et al (2014) CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res 42(W1):W401–W407
pubmed: 24861617
pmcid: 4086086
doi: 10.1093/nar/gku410
Mukwege D et al (2022) Global burden of antimicrobial resistance: essential pieces of a global puzzle. Lancet 399(10344):2348
pubmed: 35753337
doi: 10.1016/S0140-6736(22)00944-8
Murray CJ et al (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399(10325):629–655
doi: 10.1016/S0140-6736(21)02724-0
Mushtaq M et al (2021) CRISPR-based genome editing tools: insights into technological breakthroughs and future challenges. Genes 12(6):797
pubmed: 34073848
pmcid: 8225059
doi: 10.3390/genes12060797
Naduthodi MIS, Barbosa MJ, van der Oost J (2018) Progress of CRISPR-Cas based genome editing in photosynthetic microbes. Biotechnol J 13(9):1700591
doi: 10.1002/biot.201700591
Naylor NR et al (2018) Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control 7:1–17
doi: 10.1186/s13756-018-0336-y
Neil K et al (2021) High-efficiency delivery of CRISPR-Cas9 by engineered probiotics enables precise microbiome editing. Mol Syst Biol 17(10):e10335
pubmed: 34665940
pmcid: 8527022
doi: 10.15252/msb.202110335
Newsom S et al (2021) The CRISPR-Cas mechanism for adaptive immunity and alternate bacterial functions fuels diverse biotechnologies. Front Cell Infect Microbiol 10:619763
pubmed: 33585286
pmcid: 7876343
doi: 10.3389/fcimb.2020.619763
O’Connell MR (2019) Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR–Cas systems. J Mol Biol 431(1):66–87
pubmed: 29940185
doi: 10.1016/j.jmb.2018.06.029
Palermo G et al (2017) CRISPR-Cas9 conformational activation as elucidated from enhanced molecular simulations. Proc Natl Acad Sci 114(28):7260–7265
pubmed: 28652374
pmcid: 5514767
doi: 10.1073/pnas.1707645114
Park JY et al (2017) Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus. Sci Rep 7(1):44929
pubmed: 28322317
pmcid: 5359561
doi: 10.1038/srep44929
Peng D, Tarleton R (2015) EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens. Microbial Genomics 1(4):e000033
pubmed: 28348817
pmcid: 5320623
doi: 10.1099/mgen.0.000033
Perez AR et al (2017) GuideScan software for improved single and paired CRISPR guide RNA design. Nat Biotechnol 35(4):347–349
pubmed: 28263296
pmcid: 5607865
doi: 10.1038/nbt.3804
Radhouani H, Silva N, Poeta P, Torres C, Correia S, Igrejas G (2014) Potential impact of antimicrobial resistance in wildlife, environment and human health. Front Microbiol 5:23
pubmed: 24550896
pmcid: 3913889
doi: 10.3389/fmicb.2014.00023
Ray A, Di Felice R (2019) Molecular simulations have boosted knowledge of CRISPR/Cas9: a review. arXiv preprint arXiv:1904.06375
Riley MK, Vermerris W (2017) Recent advances in nanomaterials for gene delivery—a review. Nanomaterials 7(5):94
pubmed: 28452950
pmcid: 5449975
doi: 10.3390/nano7050094
Rodrigues M et al (2019) Conjugative delivery of CRISPR-Cas9 for the selective depletion of antibiotic-resistant enterococci. Antimicrob Agents Chemother 63(11). https://doi.org/10.1128/aac.01454-19
Sahu R et al (2018) Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles. Expert Rev Vaccines 17(3):217–227
pubmed: 29382248
pmcid: 6330895
doi: 10.1080/14760584.2018.1435279
Santajit S, Indrawattana N (2016) Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int 2016(1):2475067
pubmed: 27274985
pmcid: 4871955
Selle K et al (2020) In vivo targeting of Clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials. MBio. 11(2). https://doi.org/10.1128/mbio.00019-20
Shaaban EM, Ellakwa DE, Elaraby NM, Amr KS, Mohamadin AM (2022) The effect of insulin-loaded gold and carboxymethyl chitosan nanoparticles on gene expression of glucokinase and pyruvate kinase in rats with diabetes type 1. J Food Biochem 46(12):e14447
Shabbir MA et al (2018) The CRISPR-cas system promotes antimicrobial resistance in Campylobacter jejuni. Future Microbiol 13(16):1757–1774
pubmed: 30526040
doi: 10.2217/fmb-2018-0234
Shabbir MAB et al (2019) CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens. Ann Clin Microbiol Antimicrob 18:1–9
doi: 10.1186/s12941-019-0317-x
Sheng H et al (2023) Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance. PLoS ONE 18(9):e0291520
pubmed: 37699034
pmcid: 10497133
doi: 10.1371/journal.pone.0291520
Shull G et al (2019) Robotic platform for microinjection into single cells in brain tissue. EMBO Rep 20(10):e47880
pubmed: 31469223
pmcid: 6776899
doi: 10.15252/embr.201947880
Spencer SJ et al (2016) Massively parallel sequencing of single cells by epicPCR links functional genes with phylogenetic markers. ISME J 10(2):427–436
pubmed: 26394010
doi: 10.1038/ismej.2015.124
Stachler A-E et al (2020) Adaptation induced by self-targeting in a type IB CRISPR-Cas system. J Biol Chem 295(39):13502–13515
pubmed: 32723866
pmcid: 7521656
doi: 10.1074/jbc.RA120.014030
Stanley SY, Maxwell KL (2018) Phage-encoded anti-CRISPR defenses. Annu Rev Genet 52:445–464
pubmed: 30208287
doi: 10.1146/annurev-genet-120417-031321
Stern A et al (2010) Self-targeting by CRISPR: gene regulation or autoimmunity? Trends Genet 26(8):335–340
pubmed: 20598393
pmcid: 2910793
doi: 10.1016/j.tig.2010.05.008
Tacconelli E, Pezzani MD (2019) Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis 19(1):4–6
pubmed: 30409682
doi: 10.1016/S1473-3099(18)30648-0
Tagliaferri TL et al (2020) Exploring the potential of CRISPR-Cas9 under challenging conditions: facing high-copy plasmids and counteracting beta-lactam resistance in clinical strains of Enterobacteriaceae. Front Microbiol 11:578
pubmed: 32425894
pmcid: 7203346
doi: 10.3389/fmicb.2020.00578
Tang L et al (2017) CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Mol Genet Genomics 292(3):525–533
pubmed: 28251317
doi: 10.1007/s00438-017-1299-z
Theriot CM et al (2014) Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 5(1):3114
pubmed: 24445449
doi: 10.1038/ncomms4114
Tolba MM, Jabbar A, Afzal S, Mahmoud M, Zulfiqar F, El-Soudany I, ... Ellakwa DES (2023) A promising RNA nanotechnology in clinical therapeutics: a future perspective narrative review. Future Sci OA 9(8):FSO883
Uchida N et al (2021) Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Mol Ther Methods Clin Dev 21:121–132
pubmed: 33816645
pmcid: 8005818
doi: 10.1016/j.omtm.2021.02.022
Ullah K et al (2020) Enhancing the antibacterial activity of erythromycin with titanium dioxide nanoparticles against MRSA. Curr Pharm Biotechnol 21(10):948–954
pubmed: 31994459
doi: 10.2174/1389201021666200128124142
Uribe RV et al (2021) Bacterial resistance to CRISPR-Cas antimicrobials. Sci Rep 11(1):17267
pubmed: 34446818
pmcid: 8390487
doi: 10.1038/s41598-021-96735-4
van Belkum A et al (2015) Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. MBio 6(6). https://doi.org/10.1128/mbio.01796-15
Vilarino M, Rashid ST, Suchy FP, McNabb BR, Van Der Meulen T, Fine EJ, Ross PJ (2017) CRISPR/Cas9 microinjection in oocytes disables pancreas development in sheep. Sci Rep 7(1):17472
pubmed: 29234093
pmcid: 5727233
doi: 10.1038/s41598-017-17805-0
Wan F et al (2021) Novel strategy to combat antibiotic resistance: a sight into the combination of CRISPR/Cas9 and nanoparticles. Pharmaceutics 13(3):352
pubmed: 33800235
pmcid: 7998274
doi: 10.3390/pharmaceutics13030352
Wang H-X et al (2017) CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev 117(15):9874–9906
pubmed: 28640612
doi: 10.1021/acs.chemrev.6b00799
Wang Y et al (2018) Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells. Genome Biol 19:1–16
doi: 10.1186/s13059-018-1445-x
Wang G, Song G, Xu Y (2020) Association of CRISPR/Cas system with the drug resistance in Klebsiella pneumoniae. Infect Drug Resist 13:1929–1935
pubmed: 32606841
pmcid: 7320894
doi: 10.2147/IDR.S253380
Wani AK et al (2022a) Microbial adaptation to different environmental conditions: molecular perspective of evolved genetic and cellular systems. Arch Microbiol 204(2):144
pubmed: 35044532
doi: 10.1007/s00203-022-02757-5
Wani AK, Akhtar N, Shukla S (2022b) CRISPR/Cas9: regulations and challenges for law enforcement to combat its dual-use. Forensic Sci Int 334:111274
pubmed: 35316773
doi: 10.1016/j.forsciint.2022.111274
Wani AK et al (2023) Genome centric engineering using ZFNs, TALENs and CRISPR-Cas9 systems for trait improvement and disease control in animals. Vet Res Commun 47(1):1–16
pubmed: 35781172
doi: 10.1007/s11259-022-09967-8
Wani AK et al (2024) CRISPR/Cas12a-based biosensors for environmental monitoring and diagnostics. Environ Technol Innov 34:103625
doi: 10.1016/j.eti.2024.103625
Wary A (2018) Modeling the CRISPR/Cas9 structural complex with sgRNA and DNA. Cancer Res 78(13_Supplement):1374–1374
doi: 10.1158/1538-7445.AM2018-1374
Wong N, Liu W, Wang X (2015) WU-CRISPR: characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol 16:1–8
doi: 10.1186/s13059-015-0784-0
Xiang G et al (2017) Temperature effect on CRISPR-Cas9 mediated genome editing. J Genet Genomics 44(4):199–205
pubmed: 28412228
doi: 10.1016/j.jgg.2017.03.004
Xu Z et al (2019) Native CRISPR-Cas-mediated genome editing enables dissecting and sensitizing clinical multidrug-resistant P. aeruginosa. Cell Rep 29(6):1707-1717. e3
pubmed: 31693906
doi: 10.1016/j.celrep.2019.10.006
Xu Y et al (2022) An efficient CRISPR/Cas9 system for simultaneous editing two target sites in Fortunella hindsii. Hortic Res 9:uhac064
pubmed: 35673604
pmcid: 9166532
doi: 10.1093/hr/uhac064
Yin H, Xue W, Anderson DG (2019) CRISPR–Cas: a tool for cancer research and therapeutics. Nat Rev Clin Oncol 16(5):281–295
pubmed: 30664678
doi: 10.1038/s41571-019-0166-8
Yip BH (2020) Recent advances in CRISPR/Cas9 delivery strategies. Biomolecules 10(6):839
pubmed: 32486234
pmcid: 7356196
doi: 10.3390/biom10060839
Zhang J et al (2018) Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production. Metab Eng 47:49–59
pubmed: 29530750
doi: 10.1016/j.ymben.2018.03.007
Zhang Z et al (2019) Cas4 nucleases can effect specific integration of CRISPR spacers. J Bacteriol 201(12). https://doi.org/10.1128/jb.00747-18
Zhou G et al (2015) The three bacterial lines of defense against antimicrobial agents. Int J Mol Sci 16(9):21711–21733
pubmed: 26370986
pmcid: 4613276
doi: 10.3390/ijms160921711
Zhou Y et al (2023) Exploiting a conjugative endogenous CRISPR-Cas3 system to tackle multidrug-resistant Klebsiella pneumoniae. EBioMedicine 88:104445
pubmed: 36696817
pmcid: 9879765
doi: 10.1016/j.ebiom.2023.104445
Zuberi A, Ahmad N, Khan AU (2017) CRISPRi induced suppression of fimbriae gene (fimH) of a uropathogenic Escherichia coli: an approach to inhibit microbial biofilms. Front Immunol 8:1552
pubmed: 29181009
pmcid: 5694031
doi: 10.3389/fimmu.2017.01552